P
Peter A. Kaufman
Researcher at Dartmouth–Hitchcock Medical Center
Publications - 161
Citations - 13532
Peter A. Kaufman is an academic researcher from Dartmouth–Hitchcock Medical Center. The author has contributed to research in topics: Breast cancer & Metastatic breast cancer. The author has an hindex of 41, co-authored 144 publications receiving 12017 citations. Previous affiliations of Peter A. Kaufman include Dartmouth College.
Papers
More filters
Journal ArticleDOI
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
Edward H. Romond,Edith A. Perez,John Bryant,Vera J. Suman,Charles E. Geyer,Nancy E. Davidson,Elizabeth Tan-Chiu,Silvana Martino,Soonmyung Paik,Peter A. Kaufman,Sandra M. Swain,Thomas M. Pisansky,Louis Fehrenbacher,Leila A. Kutteh,Victor G. Vogel,Daniel W. Visscher,Greg Yothers,Robert B. Jenkins,Ann M. Brown,S. R. Dakhil,Eleftherios P. Mamounas,Wilma L. Lingle,Pamela M. Klein,James N. Ingle,Norman Wolmark +24 more
TL;DR: Tastuzumab combined with paclitaxel after doxorubicin and cyclophosphamide improves outcomes among women with surgically removed HER2-positive breast cancer.
Journal ArticleDOI
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy.
George W. Sledge,Masakazu Toi,Patrick Neven,Joohyuk Sohn,Kenichi Inoue,Xavier Pivot,Olga Burdaeva,Meena Okera,Norikazu Masuda,Peter A. Kaufman,Han Koh,EM Grischke,Martin Frenzel,Yong Lin,Susana Barriga,Ian C. Smith,Nawel Bourayou,Antonio Llombart-Cussac +17 more
TL;DR: Abemaciclib at 150 mg twice daily plus fulvestrant was effective, significantly improving PFS and ORR and demonstrating a tolerable safety profile in women with hormone receptor-positive and human epidermal growth factor receptor 2-negative ABC who progressed while receiving ET.
Journal ArticleDOI
Four-Year Follow-Up of Trastuzumab Plus Adjuvant Chemotherapy for Operable Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Joint Analysis of Data From NCCTG N9831 and NSABP B-31
Edith A. Perez,Edward H. Romond,Vera J. Suman,Jong-Hyeon Jeong,Nancy E. Davidson,Charles E. Geyer,Silvana Martino,Eleftherios P. Mamounas,Peter A. Kaufman,Norman Wolmark +9 more
TL;DR: These data demonstrate consistent DFS and OS advantages of adjuvant trastuzumab over time, with the longest follow-up reported to date, and the clinical benefits continue to outweigh the risks of adverse effects.
Journal ArticleDOI
Longitudinal Assessment of Cognitive Changes Associated With Adjuvant Treatment for Breast Cancer: Impact of Age and Cognitive Reserve
Tim A. Ahles,Andrew J. Saykin,Brenna C. McDonald,Yuelin Li,Charlotte T. Furstenberg,Brett Hanscom,Tamsin J. Mulrooney,Gary N. Schwartz,Peter A. Kaufman +8 more
TL;DR: Data demonstrated that age and pretreatment cognitive reserve were related to post-treatment decline in Processing Speed in women exposed to chemotherapy and that chemotherapy had a short-term impact on Verbal Ability.
Journal ArticleDOI
HER2 Testing by Local, Central, and Reference Laboratories in Specimens From the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial
Edith A. Perez,Vera J. Suman,Nancy E. Davidson,Silvana Martino,Peter A. Kaufman,Wilma L. Lingle,Patrick J. Flynn,James N. Ingle,Daniel W. Visscher,Robert B. Jenkins +9 more
TL;DR: The findings support the importance of using high-volume, experienced laboratories for HER2 testing to improve the process of selecting patients likely to benefit from trastuzumab therapy.